Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy
Metrics: PDF 2079 views | HTML 2235 views | ?
Daniel O’Neill2, Dominic Jones1, Mark Wade1, James Grey1, Sirintra Nakjang1, Wenrui Guo1, David Cork1, Barry R. Davies2, Steve R. Wedge1, Craig N. Robson1, Luke Gaughan1
1Northern Institute for Cancer Research, Newcastle University, Newcastle Upon Tyne, NE2 4HH, UK
2AstraZeneca, Innovative Medicines, Discovery Sciences, Cambridge Science Park, Cambridge, CB4 0WG, UK
Luke Gaughan, e-mail: firstname.lastname@example.org
Keywords: prostate cancer, androgen receptor, mutation, anti-androgen-resistance, SGK1
Received: March 04, 2015 Accepted: July 08, 2015 Published: July 20, 2015
The persistence of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the unmet clinical need for the development of more effective AR targeting therapies. A key mechanism of therapy-resistance is by selection of AR mutations that convert anti-androgens to agonists enabling the retention of androgenic signalling in CRPC. To improve our understanding of these receptors in advanced disease we developed a physiologically-relevant model to analyse the global functionality of AR mutants in CRPC. Using the bicalutamide-activated ARW741L/C mutation as proof of concept, we demonstrate that this mutant confers an androgenic-like signalling programme and growth promoting phenotype in the presence of bicalutamide. Transcriptomic profiling of ARW741L highlighted key genes markedly up-regulated by the mutant receptor, including TIPARP, RASD1 and SGK1. Importantly, SGK1 expression was found to be highly expressed in the KUCaP xenograft model and a CRPC patient biopsy sample both of which express the bicalutamide-activated receptor mutant. Using an SGK1 inhibitor, ARW741L transcriptional and growth promoting activity was reduced indicating that exploiting functional distinctions between receptor isoforms in our model may provide new and effective therapies for CRPC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.